Insmed (INSM) Stock Forecast & Price Target

Insmed is supported by a stronger-than-expected Brinsupri launch, with 2Q 2026 revenue of $309.2M, FY 2026 guidance lifted to $1.25B-$1.4B, and management citing payer approval, compliance, and discontinuation trends ahead of prior expectations. Its long-term thesis is reinforced by a much larger addressable U.S. bronchiectasis population, improved net pricing and persistence assumptions, and peak Brinsupri revenue now modeled above $7B, while Arikayce still supports $450M-$470M in 2026 revenue and benefits from a verified U.S. list price of $220,012 per patient-year. Beyond the commercial base, the company’s pipeline adds optionality through TPIP, INS1148, brensocatib, and INS1201, with TPIP viewed as differentiated by once-daily inhaled dosing and management raising peak potential to $6B+, helping sustain a positive fundamental outlook.

Insmed is facing a negative outlook because its valuation depends heavily on Brinsupri sustaining momentum, yet management has not disclosed one-year persistence data and the only benchmark remains the 12% discontinuation rate from ASPEN, while new patient starts could slow from the guided approximately 7,000 per quarter. Revenue quality also looks pressured by potential gross-to-net widening beyond the mid to high 20s into 2027, softer U.S. refractory Arikayce, and execution risk around frontline Arikayce approval in the U.S. and Japan, where pricing and reimbursement remain uncertain. On top of that, TPIP carries elevated development risk with reliance on a single registrational PAH study, a six-minute walk endpoint in PH-ILD, and orphan exclusivity hurdles in IPF, even with about $1.2 billion of cash and cash equivalents at the end of 2Q 2026.